Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

RWJ-67657

🥰Excellent
Catalog No. T16812Cas No. 215303-72-3
Alias JNJ 3026582

RWJ-67657 (JNJ 3026582) is an orally active, selective p38α and p38β MAPK inhibitor (IC50s: 1 and 11 μM, respectively), with no activity at p38γ and p38δ, and demonstrates cardioprotective effects.

RWJ-67657

RWJ-67657

🥰Excellent
Purity: 99.66%
Catalog No. T16812Alias JNJ 3026582Cas No. 215303-72-3
RWJ-67657 (JNJ 3026582) is an orally active, selective p38α and p38β MAPK inhibitor (IC50s: 1 and 11 μM, respectively), with no activity at p38γ and p38δ, and demonstrates cardioprotective effects.
Pack SizePriceAvailabilityQuantity
2 mg37 €In Stock
5 mg60 €In Stock
10 mg92 €In Stock
25 mg216 €In Stock
50 mg349 €In Stock
100 mg563 €In Stock
500 mg1.187 €In Stock
1 mL x 10 mM (in DMSO)66 €In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "RWJ-67657"

Select Batch
Purity:99.66%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
RWJ-67657 (JNJ 3026582) is an orally active, selective p38α and p38β MAPK inhibitor (IC50s: 1 and 11 μM, respectively), with no activity at p38γ and p38δ, and demonstrates cardioprotective effects.
Targets&IC50
p38α:1 μM, p38β:11 μM
In vitro
RWJ-67657 suppresses the release of TNF-α by lipopolysaccharide (LPS)-treated human peripheral blood mononuclear cells (IC50: 3 nM) and the release of TNF-α from peripheral blood mononuclear cells treated with the superantigen staphylococcal enterotoxin B (IC50: 13 nM). RWJ67657 (10 μM; 24 hours) reduces colony formation in MCF-7 cells [2][3].
In vivo
RWJ-67657 inhibits TNF-alpha production in lipopolysaccharide-injected mice (87% inhibition at 50 mg/kg) and in rats (91% inhibition at 25 mg/kg) after oral administration. RWJ-67657 (50 mg/kg; p.o.; once daily for 7 consecutive days) demonstrates effective anti-inflammatory activity. EPC transplantation combined with RWJ-67657 administration synergistically promotes angiogenesis and neurogenesis following diabetic stroke by enhancing endothelial progenitor cell function and reducing inflammation [2][4].
AliasJNJ 3026582
Chemical Properties
Molecular Weight425.5
FormulaC27H24FN3O
Cas No.215303-72-3
SmilesOCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1
Relative Density.1.14 g/cm3 (Predicted)
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 125 mg/mL (293.77 mM), Sonication and heating to 60℃ are recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.3502 mL11.7509 mL23.5018 mL117.5088 mL
5 mM0.4700 mL2.3502 mL4.7004 mL23.5018 mL
10 mM0.2350 mL1.1751 mL2.3502 mL11.7509 mL
20 mM0.1175 mL0.5875 mL1.1751 mL5.8754 mL
50 mM0.0470 mL0.2350 mL0.4700 mL2.3502 mL
100 mM0.0235 mL0.1175 mL0.2350 mL1.1751 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy RWJ-67657 | purchase RWJ-67657 | RWJ-67657 cost | order RWJ-67657 | RWJ-67657 chemical structure | RWJ-67657 in vivo | RWJ-67657 in vitro | RWJ-67657 formula | RWJ-67657 molecular weight